AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates.
Company facts
| Company | AbCellera Biologics Inc. |
|---|---|
| Symbol | ABCL |
| Exchange | XNAS |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $3.39B (Massive market data, 2026-09-10) |
| Employees | 562 |
| Country | Canada |
| Website | https://www.abcellera.com |
Trading — AbCellera Biologics Inc.
| Last price | $10.83 |
|---|---|
| Change | 3.54% |
| Previous close | $10.46 |
| Day range | $10.32 – $10.96 |
| 50-day average | $8.61 |
| 200-day average | $5.25 |
| Average volume | 5,713,964 |
Price basis: massive_snapshot_price · 2026-09-11T21:10:28.023989+00:00
Valuation and financial health
| Earnings per share | $-0.51 |
|---|---|
| Price / book | 3.78 |
| Enterprise value / EBITDA | -15.91 |
| Enterprise value / sales | 49.41 |
| Debt / equity | 0.00 |
| Current ratio | 12.77 |
| Dividend yield | 0.00% |
| Free cash flow | -$119.67M |
| Cash ratio | 2.26 |
| Enterprise value | $3.27B |
Reported 2026-09-10
Earnings
| Report date | 2026-11-05 |
|---|---|
| Session | After Hours |
| Fiscal quarter ending | 2026-09-30 |
| EPS estimate | -0.18 |
Source: optionsai supplemental public earnings calendar
Other Healthcare companies
Live data
Live quotes, options positioning, insider and congressional filings for ABCL are on the IntelTrends dashboard.